JP6535133B2 - 新規のバキュロウイルスベクター及び使用の方法 - Google Patents
新規のバキュロウイルスベクター及び使用の方法 Download PDFInfo
- Publication number
- JP6535133B2 JP6535133B2 JP2018511354A JP2018511354A JP6535133B2 JP 6535133 B2 JP6535133 B2 JP 6535133B2 JP 2018511354 A JP2018511354 A JP 2018511354A JP 2018511354 A JP2018511354 A JP 2018511354A JP 6535133 B2 JP6535133 B2 JP 6535133B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- virus
- baculovirus
- recombinant baculovirus
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701447 unidentified baculovirus Species 0.000 title claims description 111
- 239000013598 vector Substances 0.000 title claims description 64
- 238000000034 method Methods 0.000 title description 7
- 101001001300 Human cytomegalovirus (strain Towne) 65 kDa phosphoprotein Proteins 0.000 claims description 85
- 239000000427 antigen Substances 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 241000700605 Viruses Species 0.000 claims description 38
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000004899 c-terminal region Anatomy 0.000 claims description 27
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 22
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 18
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 244000052769 pathogen Species 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 241000282898 Sus scrofa Species 0.000 claims description 11
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 10
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 241000238631 Hexapoda Species 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 206010008631 Cholera Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000009851 immunogenic response Effects 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 5
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 claims description 4
- 241001673669 Porcine circovirus 2 Species 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims description 3
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 27
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 241000282887 Suidae Species 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 7
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 230000028993 immune response Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 101150045064 gp64 gene Proteins 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000034303 cell budding Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 2
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108700025184 hepatitis B virus X Proteins 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 1
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710189136 Envelope fusion protein Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 1
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 1
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 101150087384 PDCD1 gene Proteins 0.000 description 1
- 101710106089 Protein cutoff Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
本発明は一般に、組換えバキュロウイルスに関する。
バキュロウイルスは昆虫に感染し、ヒトには非病原性である。しかし、幅広い範囲のほ乳類及び鳥類細胞に形質導入することができる。バイオセーフティ、大きいクローニング能力、形質導入された細胞における低い細胞毒性及び非複製性、並びに操作及び生産の容易さのおかげで、バキュロウイルスは、抗ウイルス治療、がん治療、再生医療及びワクチンなどの、幅広い用途のための遺伝子送達ベクターとして、爆発的な人気を得ている。
一つの態様において、本発明は、融合タンパク質をコードする導入遺伝子を含むベクターに関するものであり、融合タンパク質が、(a)融合タンパク質のN末端に位置するシグナルペプチド;(b)異種抗原;及び(c)バキュロウイルスエンベロープGP64タンパク質のC末端領域であって、少なくとも100のアミノ酸残基長を有し、且つGP64タンパク質の中央塩基性領域内に位置するB12D5結合エピトープを欠く、バキュロウイルスエンベロープGP64タンパク質のC末端領域を含み、異種抗原が、シグナルペプチドとGP64タンパク質のC末端領域との間に位置する。
本発明は、以下の実施例においてより具体的に説明されている。これらの実施例は、単なる例示であることが意図される。なぜなら、実施例における多数の改変及び変更が当業者には明らかであるためである。本発明の様々な実施形態をここで詳細に説明する。図面を参照すると、図面全体において、類似の番号は、類似の構成要素を示す。この詳細な説明において、及び以下に続く特許請求の範囲全体において使用されるように、「a」、「an」、及び「the」の意味は、文脈上他に明確に指示されない限り、複数形の参照を含む。また、この詳細な説明において、及び以下に続く特許請求の範囲全体において使用されるように、「in」の意味は、文脈上他に明確に指示されない限り、「in」及び「on」を含む。さらに、読者の便宜のために、タイトル又はサブタイトルが明細書中で使用され得る。このことは、本発明の範囲に影響を与えるものではない。加えて、この明細書において使用されるいくつかの用語が、以下により具体的に定義される。
ベクターの構築及び組換えバキュロウイルス、ウイルス様粒子、及びタンパク質の生成
タンパク質発現及び抗原の精製
組換えウイルスによる抗原の発現
ワクチン調製及び免疫化
組換えウイルスによって産生された抗原の免疫原性
Claims (15)
- エンベロープ上に融合タンパク質を提示する、組換えバキュロウイルスであって、前記融合タンパク質が、
(i)異種抗原;及び
(ii)バキュロウイルスエンベロープGP64タンパク質のC末端領域であって、少なくとも100のアミノ酸残基長を有し、且つ前記GP64タンパク質の中央塩基性領域内に位置する配列番号:2又は3のアミノ酸配列から成るB12D5結合エピトープを欠く、バキュロウイルスエンベロープGP64タンパク質のC末端領域
を含み、
前記異種抗原が、前記組換えバキュロウイルスの前記エンベロープ上に提示される前記融合タンパク質のN末端に位置する、
組換えバキュロウイルス。 - 請求項1に記載の組換えバキュロウイルスであって、そのゲノムが、融合タンパク質をコードする導入遺伝子を含み、前記融合タンパク質が、
(a)シグナルペプチド;
(b)前記異種抗原;及び
(c)前記バキュロウイルスエンベロープGP64タンパク質の前記C末端領域
を含み、
前記異種抗原が、前記シグナルペプチドのC末端に位置する、
組換えバキュロウイルス。 - 融合タンパク質をコードする導入遺伝子を含むベクターであって、前記融合タンパク質が、
(a)前記融合タンパク質のN末端に位置するシグナルペプチド;
(b)異種抗原;及び
(c)バキュロウイルスエンベロープGP64タンパク質のC末端領域であって、少なくとも100のアミノ酸残基長を有し、且つ前記GP64タンパク質の中央塩基性領域内に位置する配列番号:2又は3のアミノ酸配列から成るB12D5結合エピトープを欠く、バキュロウイルスエンベロープGP64タンパク質のC末端領域
を含み、
前記異種抗原が、前記シグナルペプチドのC末端に位置する、
ベクター。 - 組換えバキュロウイルスである、請求項3に記載のベクター。
- エンベロープ上に融合タンパク質を提示する、組換えバキュロウイルスであって、前記融合タンパク質が、
(i)異種抗原;及び
(ii)バキュロウイルスエンベロープGP64タンパク質のC末端領域であって、少なくとも100のアミノ酸残基長を有し、且つ配列番号:4のアミノ酸配列から成る前記GP64タンパク質の中央塩基性領域内に位置するB12D5結合エピトープを欠く、バキュロウイルスエンベロープGP64タンパク質のC末端領域
を含み、
前記異種抗原が、前記組換えバキュロウイルスの前記エンベロープ上に提示される前記融合タンパク質のN末端に位置する、
組換えバキュロウイルス。 - 融合タンパク質をコードする導入遺伝子を含むベクターであって、前記融合タンパク質が、
(a)前記融合タンパク質のN末端に位置するシグナルペプチド;
(b)異種抗原;及び
(c)バキュロウイルスエンベロープGP64タンパク質のC末端領域であって、少なくとも100のアミノ酸残基長を有し、且つ配列番号:4のアミノ酸配列から成る前記GP64タンパク質の中央塩基性領域内に位置するB12D5結合エピトープを欠く、バキュロウイルスエンベロープGP64タンパク質のC末端領域
を含み、
前記異種抗原が、前記シグナルペプチドのC末端に位置する、
ベクター。 - 前記GP64タンパク質の前記C末端領域が、配列番号:1の327〜512のアミノ酸を含む、請求項1に記載の組換えバキュロウイルス。
- 前記GP64タンパク質の前記C末端領域のN末端が、配列番号:1の292〜328のアミノ酸残基に位置する、請求項1に記載の組換えバキュロウイルス。
- 前記シグナルペプチドが、配列番号:5、6、7、8、9、10、11、及び12からなる群より選択されるアミノ酸配列を含む、請求項2に記載の組換えバキュロウイルス。
- 請求項1に記載の組換えバキュロウイルスで形質導入された昆虫細胞。
- 前記抗原が、病原体タンパク質、がん細胞タンパク質、及び免疫チェックポイントタンパク質からなる群より選択される少なくとも1つである、請求項1に記載の組換えバキュロウイルス。
- 請求項11に記載の組換えバキュロウイルスであって、
(i)前記病原体が、ヒトパピローマウイルス、ブタ生殖器呼吸器症候群ウイルス、ヒト免疫不全ウイルス−1、デングウイルス、C型肝炎ウイルス、B型肝炎ウイルス、ブタサーコウイルス2、ブタコレラウイルス、口蹄疫ウイルス、ニューカッスル病ウイルス、伝染性胃腸炎ウイルス、ブタ流行性下痢ウイルス、インフルエンザウイルス、仮性狂犬病ウイルス、パルボウイルス、ブタ水疱病ウイルス、ポックスウイルス、ロタウイルス、マイコプラズマ肺炎、ヘルペスウイルス、感染性気管支炎、及び感染性嚢胞疾患ウイルスからなる群より選択される少なくとも1つであり;
(ii)前記がんが、非小細胞肺がん、乳がん、メラノーマ、リンパ腫、結腸がん、肝細胞がん、及びそれらの任意の組み合わせからなる群より選択される少なくとも1つであり;
(iii)前記免疫チェックポイントが、PD−1、PD−L1、PD−L2、及びCTLA−4からなる群より選択される少なくとも1つである、
組換えバキュロウイルス。 - 前記抗原が、ブタコレラウイルスエンベロープ糖タンパク質E2、ブタ流行性下痢ウイルスS1タンパク質、プログラム細胞死タンパク質1、及び腫瘍関連抗原からなる群より選択される少なくとも1つである、請求項1に記載の組換えバキュロウイルス。
- 前記抗原が、病原体タンパク質、がん細胞タンパク質、及び免疫チェックポイントタンパク質からなる群より選択される少なくとも1つである、請求項3に記載のベクター。
- 抗原特異的免疫原性応答を、それを必要とする被験体において誘発することでの治療のための、医薬品の製造における、請求項3に記載のベクター又は請求項1に記載の組換えバキュロウイルスの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562162139P | 2015-05-15 | 2015-05-15 | |
US62/162,139 | 2015-05-15 | ||
PCT/US2016/032421 WO2016187027A1 (en) | 2015-05-15 | 2016-05-13 | Novel baculovirus vectors and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018515141A JP2018515141A (ja) | 2018-06-14 |
JP6535133B2 true JP6535133B2 (ja) | 2019-06-26 |
Family
ID=57276429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018511354A Active JP6535133B2 (ja) | 2015-05-15 | 2016-05-13 | 新規のバキュロウイルスベクター及び使用の方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10172931B2 (ja) |
EP (1) | EP3294329B1 (ja) |
JP (1) | JP6535133B2 (ja) |
KR (1) | KR102025488B1 (ja) |
CN (1) | CN107921115B (ja) |
CA (1) | CA2985227C (ja) |
DK (1) | DK3294329T3 (ja) |
ES (1) | ES2787261T3 (ja) |
TW (1) | TWI605124B (ja) |
WO (1) | WO2016187027A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109280675A (zh) * | 2017-07-21 | 2019-01-29 | 百卫生物科技股份有限公司 | 用于增强蛋白质表达的表达盒、载体、病毒及疫苗 |
CN109824779B (zh) * | 2017-11-23 | 2023-05-26 | 中山大学 | 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白 |
TWI744654B (zh) * | 2018-06-25 | 2021-11-01 | 中央研究院 | 用於偵測及預防豬流行性下痢病毒感染的桿狀病毒及組合物 |
CN109182380B (zh) * | 2018-08-14 | 2022-06-03 | 浙江大学 | 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用 |
EP3867362A4 (en) * | 2018-10-18 | 2022-08-03 | Academia Sinica | METHOD AND KIT FOR DETECTING PESTICIDES AND PLASMID, BACULOVIRUS, CELL AND METHOD FOR THEIR MANUFACTURE FOR PESTICIDE DETECTION |
CN109400684B (zh) * | 2018-11-15 | 2021-08-06 | 河南省农业科学院 | 一种pedv s-rbd线性b细胞表位及两株特异性识别单克隆抗体和应用 |
CN110066827B (zh) * | 2019-04-29 | 2020-12-15 | 华中农业大学 | 含猪伪狂犬病病毒gB蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用 |
TWI774032B (zh) * | 2019-08-02 | 2022-08-11 | 中央研究院 | 用於非洲豬瘟病毒蛋白的重組桿狀病毒及其免疫組成物 |
CN112159480B (zh) * | 2020-10-15 | 2022-03-22 | 福建农林大学 | 一种鸡传染性法氏囊病病毒多抗原表位蛋白及其应用 |
CN113318223B (zh) * | 2021-04-22 | 2021-12-31 | 湖南兀邦生物科技有限公司 | 猪瘟病毒与猪流行性腹泻病毒亚单位联合疫苗及其制备方法 |
CN114262720B (zh) * | 2021-12-27 | 2023-07-25 | 河南兴华生物技术有限公司 | 杆状病毒表达系统的信号肽及其应用 |
CN117143888B (zh) * | 2023-08-29 | 2024-08-13 | 上海杰威医药科技有限公司 | 一种猪圆环病毒2a、2b、2d型三价病毒样颗粒疫苗及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0784483T3 (da) * | 1994-10-03 | 2001-03-26 | Us Gov Health & Human Serv | Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul |
NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
CN1338310A (zh) * | 2000-08-10 | 2002-03-06 | 清华大学 | 一种猪瘟病毒表位疫苗及其制备方法 |
WO2003104453A1 (ja) * | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
US7527967B2 (en) * | 2003-11-25 | 2009-05-05 | Academia Sinica | Recombinant baculovirus and virus-like particle |
ATE432353T1 (de) * | 2004-07-27 | 2009-06-15 | Riken | Vektor zur expression von humaner n-deacetylase/n-sulfotransferase 2 |
WO2009009215A2 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
US8703469B2 (en) * | 2007-07-06 | 2014-04-22 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
US20110201086A1 (en) * | 2010-02-12 | 2011-08-18 | Otsuka Pharmaceutical Co., Ltd. | Method for producing recombinant virus |
EP2654787A1 (en) * | 2010-12-22 | 2013-10-30 | Novavax, Inc. | Modified influenza hemagglutinin proteins and uses thereof |
WO2013056716A1 (en) * | 2011-10-17 | 2013-04-25 | Herlev Hospital | Pd-l1 based immunotherapy |
JP5830486B2 (ja) * | 2013-03-29 | 2015-12-09 | シスメックス株式会社 | 組換えバキュロウイルスおよびその利用 |
-
2016
- 2016-05-13 CN CN201680028075.8A patent/CN107921115B/zh active Active
- 2016-05-13 ES ES16797022T patent/ES2787261T3/es active Active
- 2016-05-13 JP JP2018511354A patent/JP6535133B2/ja active Active
- 2016-05-13 US US15/153,851 patent/US10172931B2/en active Active
- 2016-05-13 EP EP16797022.7A patent/EP3294329B1/en active Active
- 2016-05-13 CA CA2985227A patent/CA2985227C/en active Active
- 2016-05-13 WO PCT/US2016/032421 patent/WO2016187027A1/en unknown
- 2016-05-13 DK DK16797022.7T patent/DK3294329T3/da active
- 2016-05-13 TW TW105114854A patent/TWI605124B/zh active
- 2016-05-13 KR KR1020177036148A patent/KR102025488B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20160331826A1 (en) | 2016-11-17 |
US10172931B2 (en) | 2019-01-08 |
JP2018515141A (ja) | 2018-06-14 |
KR20180002872A (ko) | 2018-01-08 |
KR102025488B1 (ko) | 2019-09-25 |
DK3294329T3 (da) | 2020-05-04 |
CN107921115B (zh) | 2021-04-20 |
EP3294329B1 (en) | 2020-04-15 |
ES2787261T3 (es) | 2020-10-15 |
TW201712119A (zh) | 2017-04-01 |
EP3294329A1 (en) | 2018-03-21 |
CA2985227C (en) | 2021-05-04 |
TWI605124B (zh) | 2017-11-11 |
WO2016187027A1 (en) | 2016-11-24 |
CN107921115A (zh) | 2018-04-17 |
CA2985227A1 (en) | 2016-11-24 |
EP3294329A4 (en) | 2018-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6535133B2 (ja) | 新規のバキュロウイルスベクター及び使用の方法 | |
CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
US9676826B2 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses | |
Green et al. | C3d enhancement of neutralizing antibodies to measles hemagglutinin | |
Kim et al. | Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets | |
JP6676661B2 (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
WO2022135563A1 (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
JP2023523423A (ja) | SARS-CoV-2に対するワクチン及びその調製物 | |
WO2021253172A1 (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
Kim et al. | DNA vaccination against foot‐and‐mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity | |
EP3347044A1 (en) | Bird flu vaccine combination comprising virus-like particles and novel adjuvants | |
Wang et al. | Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d | |
KR102399308B1 (ko) | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 | |
US20230338511A1 (en) | Single-chain coronavirus viral membrane protein complexes | |
WO2021235503A1 (ja) | コロナウイルスの蛋白質が担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン | |
CN113801206A (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
US11607449B2 (en) | Synthetic plasmid DNA vaccine expressing a codon-optimized SARS-COV-2 spike protein | |
JP2012139193A (ja) | 融合タンパク質 | |
KR20220063760A (ko) | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 | |
KR20230157180A (ko) | 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 | |
KR20130001559A (ko) | 넓은 범위의 교차 방어능력을 갖는 신규한 보강 인플루엔자 백신 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190528 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6535133 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |